3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
25
Neoplasm Metastasis
5
Neoplasms
3
Brain Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Salivary Gland Neoplasms
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Lung Neoplasms
2
Hematologic Neoplasms
2
HER2-positive Breast Cancer
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Patient Preference
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neoplasm, Residual
1
Melanoma
1
Inflammatory Breast Neoplasms
1
Interventions
Paclitaxel
7
Cyclophosphamide
6
Doxorubicin
5
pembrolizumab
3
eribulin
3
Trastuzumab
3
Taxes
3
Specimen Handling
3
Carboplatin
3
pertuzumab
2
Radiotherapy
2
Epirubicin
2
Docetaxel
2
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
ruxolitinib
1
pegfilgrastim
1
onvansertib
1
olaparib
1
neratinib
1
grapiprant
1
durvalumab
1
cobimetinib
1
caficrestat
1
atezolizumab
1
X-Rays
1
Therapeutics
1
Tamoxifen
1
Surgical Procedures, Operative
1
Radiation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Inflammatory Breast Neoplasms
×
Ado-Trastuzumab Emtansine
×
1 year
×
Clear all
NCT05415215
2026-02-10
ProHer
Hoffmann-La Roche
Phase 3
Completed
346 enrolled
20 charts